Clinical Trial Update: To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of SCB01A in recurrent/metastatic squamous cell carcinoma of the head and neck was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Cancer

Drugs mentioned

• SCB01A

Snippet

Sponsor: SynCore Biotechnology Co., Ltd. | Conditions: Head and Neck Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2023-06-02